Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B (Gut (2016) 65 (1514-1521) DOI: 10.1136/gutjnl-2015-310686);The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B

Gut

Volumn 65, Issue 9, 2016, Pages 1514-1521

  Hu, Hui Han ^a   Liu, Jessica ^a   Lin, Yu Ling ^a   Luo, Wun Sheng ^a   Chu, Yu Ju ^a   Chang, Chia Lin ^a   Jen, Chin Lan ^a   Lee, Mei Hsuan ^b   Lu, Sheng Nan ^c   Wang, Li Yu ^d   You, San Lin ^a   Yang, Hwai I ^a,b   Chen, Chien Jen ^a,e  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d MACKAY MEDICAL COLLEGE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chronic hepatitis; cirrhosis; genetic polymorphisms; hepatocellular carcinoma

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; PHENYLALANINE; SERINE; SODIUM BILE ACID COTRANSPORTER; VIRUS DNA; COTRANSPORTER; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ADULT; ARTICLE; CHRONIC HEPATITIS B; DISEASE COURSE; DNA DETERMINATION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFECTION RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC10A1 GENE; CARCINOMA, HEPATOCELLULAR; COMPLICATION; EPIDEMIOLOGY; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; PHYSIOLOGY; PROTECTION; TAIWAN;

ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTECTIVE FACTORS; SYMPORTERS; TAIWAN;

EID: 84954305928     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310686corr1     Document Type: Erratum

References (33)

1. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38(10 Suppl 3):S158-68.
2. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15(Suppl):E3-6.
3. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92.
4. Liu J, Yang HI, Lee MH, et al. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology 2014;60:77-86.
5. Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013;58:853-60.
6. Yang HI, Lee MH, Liu J, et al. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol 2014;20:6244-51.
7. Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546-54.
8. Liu J, Yang HI, Lee MH, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014;63:1648-57.
9. Baumert TF, Meredith L, Ni Y, et al. Entry of hepatitis B and C viruses-recent progress and future impact. Curr Opin Virol 2014;4:58-65.
10. Barrera A, Guerra B, Notvall L, et al. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J Virol 2005;79:9786-98.
11. Glebe D, Urban S, Knoop EV, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005;129:234-45.
12. Schieck A, Schulze A, Gähler C, et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology 2013;58:43-53.
13. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012;1:e00049.
14. Yan H, Peng B, He W, et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 2013;87:7977-91.
15. Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014;146:1070-83.
16. Ho RH, Leake BF, Roberts RL, et al. Ethnicity-dependent polymorphism in Na +-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 2004;279:7213-22.
17. Pan W, Song IS, Shin HJ, et al. Genetic polymorphisms in Na+-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica 2011;41:501-10.
18. Watashi K, Urban S, Li W, et al. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci 2014;15:2892-905.
19. Li N, Zhang P, Yang C, et al. Association of genetic variation of sodium taurocholate cotransporting polypeptide with chronic hepatitis B virus infection. Genet Test Mol Biomarkers 2014;18:425-9.
20. Peng L, Zhao Q, Li Q, et al. The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology 2015;61:1251-60.
21. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011;26:628-38.
22. Mareninova O, Shin JM, Vagin O, et al. Topography of the membrane domain of the liver Na+-dependent bile acid transporter. Biochemistry 2005;44:13702-12.
23. Yan H, Peng B, Liu Y, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol 2014;88:3273-84.
24. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005;54:1024-33.
25. Miyoshi H, Rust C, Roberts PJ, et al. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999;117:669-77.
26. Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999;103:137-45.
27. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41.
28. Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 2014;59:1726-37.
29. Nkongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014;60:723-31.
30. Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res 2013;97:195-7.
31. Huang HC, Tao MH, Hung TM, et al. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res 2014;111:100-11.
32. Kim RB, Leake B, Cvetkovic M, et al. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther 1999;291:1204-9.
33. Fu LL, Liu J, Chen Y, et al. In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. Cell Prolif 2014;47:326-35.